Santa Clarita-based Specialty Laboratories Inc.’s chief financial officer is stepping down to “pursue other opportunities,” the company announced Wednesday.
The resignation comes two months after the laboratory’s chief executive officer and chairman announced their resignations.
Kevin R. Sayer, Specialty’s chief financial officer, had been the company’s acting CEO since March 29, when Douglas S. Harrington resigned. Sayer’s resignation is effective May 16.
Specialty’s controller, Kevin W. Johnson, is set oversee the company’s finances and accounting upon Sayer’s departure.
Sayer’s resignation follows a company warning in April that it may continue to experience future quarterly losses as a result of its recovery efforts.
For the first quarter, the laboratory reported a net loss of $10.2 million, or 44 cents a share, compared to a net loss of $2.5 million, or 11 cents a share, during the same period the year prior.
Also on Wednesday, Specialty announced that it was replacing its senior vice president of sales and marketing.
Laboratory executive Victoria DiFrancesco is set to replace Mark R. Willig as the head of Specialty’s sales unit on June 1.
Specialty chairman Richard K. Whitney, who was appointed to the position in February following the resignation of Richard E. Belluzzo, said he was grateful for Willig’s and Sayer’s contributions to the company.
“Under their leadership, Specialty has regained its sales momentum and strengthened its leadership position as a national provider of specialized clinical testing,” Whitney said in a statement. “We wish both Kevin and Mark the very best in their future pursuits.”
Whitney said Specialty is currently searching for a permanent chief executive officer and new chief financial officer.
Specialty is a clinical laboratory for more than 10,000 hospitals and physicians in the United States.
On Wednesday, shares of the company fell 12.53 percent or $1.02 to $7.12 on the New York Stock Exchange.
